Payment overview · 2025
General Payments
$1,005.24
30 reported records · 16 companies
Healthcare provider profile · identity verified
Krishdeep Khosla, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OAKBROOK TERRACE, IL · NPI 1306899570
Verified facts
What the public records show
CMS Open Payments records show Krishdeep Khosla, MD received $1,005.24 in general payments during 2025 across 30 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 20.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lumigan by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bavarian Nordic A/S reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RabAvert as an associated drug or biological on 10 records involving 10 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rabavert by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 3936 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 822 claims for Eliquis by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Austedo by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $207.29 | 20.6% | 6 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $202.80 | 20.2% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $134.16 | 13.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $124.45 | 12.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.84 | 4.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.93 | 4.6% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $35.87 | 3.6% | 1 | 2025 |
| Bavarian Nordic A/S | Unresolved — no canonical attribution shown | $31.15 | 3.1% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.84 | 3.1% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $24.15 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.70 | 2.4% | 1 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.82 | 2.3% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $21.13 | 2.1% | 1 | 2025 |
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.94 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.17 | 1.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.00 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,005.24 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $207.29 | 6 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $202.80 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $134.16 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $124.45 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $35.87 | 1 | 2025 |
Source payment records
|
|||||
| Vivotif Normalized: vivotif |
Drug | Bavarian Nordic A/S | $31.15 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $28.29 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $24.15 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $22.37 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $21.13 | 1 | 2025 |
Source payment records
|
|||||
| REBYOTA Normalized: rebyota |
Biological | Ferring Pharmaceuticals Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 822 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
80 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bavarian Nordic A/S Exact reporting entity; no affiliate inference |
2025 | RabAvert open payments reported associated product |
CMS Open Payments — General Payments 10 supporting records · 10 recipient NPIs · example record 1250212645 |
Rabavert · 2024 Exact normalized brand match · 1 Part D row |
32 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
171 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
3936 | 3934 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
822 | 82 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 23995 | 23880 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22911 | 16827 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 8865 | 8821 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 3936 | 3934 |
| Atorvastatin Calcium | Atorvastatin Calcium | 2101 | 249 |
| Twinrix | Hepatitis A And B Vaccine/Pf | 1353 | 855 |
| Amlodipine Besylate | Amlodipine Besylate | 951 | 134 |
| Eliquis | Apixaban | 822 | 82 |
| Levothyroxine Sodium | Levothyroxine Sodium | 746 | 90 |
| Gabapentin | Gabapentin | 694 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 673 | 98 |
| Levetiracetam | Levetiracetam | 561 | 40 |
| Metformin Hcl | Metformin Hcl | 551 | 57 |
| M-M-R Ii Vaccine | Measles,mumps,rubella Vacc/Pf | 546 | 416 |
| Quetiapine Fumarate | Quetiapine Fumarate | 538 | 60 |
| Potassium Chloride | Potassium Chloride | 514 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 506 | 65 |
| Furosemide | Furosemide | 503 | 84 |
| Carvedilol | Carvedilol | 497 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 490 | 61 |
| Mirtazapine | Mirtazapine | 489 | 38 |
| Memantine Hcl | Memantine Hcl | 454 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 437 | 71 |
| Lisinopril | Lisinopril | 417 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 404 | 57 |
| Donepezil Hcl | Donepezil Hcl | 358 | 31 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 343 | 342 |
| Hydralazine Hcl | Hydralazine Hcl | 332 | 60 |
| Losartan Potassium | Losartan Potassium | 329 | 45 |
| Trazodone Hcl | Trazodone Hcl | 328 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 295 | 36 |
| Sertraline Hcl | Sertraline Hcl | 289 | 32 |
| Omeprazole | Omeprazole | 247 | 41 |
| Risperidone | Risperidone | 242 | 27 |
| Allopurinol | Allopurinol | 236 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 234 | 47 |
| Simvastatin | Simvastatin | 229 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 221 | 115 |
| Baclofen | Baclofen | 221 | 31 |
| Havrix | Hepatitis A Virus Vaccine/Pf | 219 | 200 |
| Tramadol Hcl | Tramadol Hcl | 217 | 46 |
| Enoxaparin Sodium | Enoxaparin Sodium | 216 | 22 |
| Famotidine | Famotidine | 210 | 31 |
| Divalproex Sodium | Divalproex Sodium | 199 | 31 |
| Azithromycin | Azithromycin | 190 | 170 |
| Gvoke Hypopen 2-Pack | Glucagon | 190 | 178 |
| Midodrine Hcl | Midodrine Hcl | 189 | 32 |
| Benztropine Mesylate | Benztropine Mesylate | 185 | 18 |
| Heparin Sodium | Heparin Sodium,porcine | 183 | 27 |
| Jardiance | Empagliflozin | 171 | 20 |
| Typhim Vi | Typhoid Vi Polysacch Vaccine | 171 | 170 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 152 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 143 | 17 |
| Finasteride | Finasteride | 139 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 137 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 135 | 18 |
| Latanoprost | Latanoprost | 131 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 15 |
| Xarelto | Rivaroxaban | 130 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 123 | 31 |
| Nifedipine Er | Nifedipine | 123 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 118 | suppressed |
| Myrbetriq | Mirabegron | 118 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 107 | 31 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 102 | 52 |
| Montelukast Sodium | Montelukast Sodium | 101 | 22 |
| Amantadine | Amantadine Hcl | 99 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 98 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 97 | 51 |
| Januvia | Sitagliptin Phosphate | 95 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 92 | suppressed |
| Atovaquone-Proguanil Hcl | Atovaquone/Proguanil Hcl | 91 | 89 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 89 | 86 |
| Spironolactone | Spironolactone | 88 | 18 |
| Sucralfate | Sucralfate | 88 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 86 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 86 | 17 |
| Lorazepam | Lorazepam | 85 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 82 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 82 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 80 | suppressed |
| Olanzapine | Olanzapine | 77 | 21 |
| Warfarin Sodium | Warfarin Sodium | 77 | suppressed |
| Bumetanide | Bumetanide | 74 | 19 |
| Glipizide | Glipizide | 72 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 71 | 11 |
| Haloperidol Decanoate | Haloperidol Decanoate | 69 | suppressed |
| Torsemide | Torsemide | 69 | suppressed |
| Epinephrine | Epinephrine | 68 | 68 |
| Breo Ellipta | Fluticasone/Vilanterol | 66 | 13 |
| Buspirone Hcl | Buspirone Hcl | 66 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 66 | suppressed |
| Primidone | Primidone | 66 | suppressed |
| Carbamazepine | Carbamazepine | 64 | suppressed |
| Fenofibrate | Fenofibrate | 63 | suppressed |
| Gemtesa | Vibegron | 63 | suppressed |
| Ipol | Poliomyelitis Vaccine, Killed | 62 | 61 |
| Menquadfi | Mening Vac A,c,y,w135,c-Tet/Pf | 62 | 60 |
| Propranolol Hcl | Propranolol Hcl | 62 | suppressed |
| Entresto | Sacubitril/Valsartan | 61 | suppressed |
| Lactulose | Lactulose | 60 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 60 | suppressed |
| Prednisone | Prednisone | 58 | 30 |
| Enulose | Lactulose | 56 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 56 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 56 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 55 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 54 | suppressed |
| Tradjenta | Linagliptin | 54 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 52 | suppressed |
| Cephalexin | Cephalexin | 51 | 39 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Epogen | Epoetin Alfa | 49 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 49 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 15 |
| Calcium Acetate | Calcium Acetate | 48 | suppressed |
| Phenobarbital | Phenobarbital | 48 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 47 | 34 |
| Nystatin | Nystatin | 47 | 25 |
| Sodium Chloride | 0.9 % Sodium Chloride | 47 | 25 |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Ezetimibe | Ezetimibe | 43 | suppressed |
| Meloxicam | Meloxicam | 43 | 11 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 42 | suppressed |
| Topiramate | Topiramate | 42 | suppressed |
| Yf-Vax | Yellow Fever Vaccine Live/Pf | 42 | 42 |
| Clonazepam | Clonazepam | 41 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | 13 |
| Lidocaine | Lidocaine | 41 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 39 | suppressed |
| Gvoke Hypopen 1-Pack | Glucagon | 39 | 37 |
| Sevelamer Carbonate | Sevelamer Carbonate | 39 | 15 |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | suppressed |
| Alprazolam | Alprazolam | 37 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 37 | 13 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Gardasil 9 | Hpv Vaccine 9-Valent/Pf | 36 | 27 |
| Lamotrigine | Lamotrigine | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 29 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 35 | 12 |
| Haloperidol Lactate | Haloperidol Lactate | 35 | 17 |
| Insulin Lispro | Insulin Lispro | 35 | 14 |
| Levofloxacin | Levofloxacin | 35 | 24 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 33 | 18 |
| Levocarnitine | Levocarnitine (With Sugar) | 32 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 32 | suppressed |
| Rabavert | Rabies Vaccine (Pcec)/Pf | 32 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Fiasp | Insulin Aspart (Niacinamide) | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 15 |
| Theophylline Er | Theophylline Anhydrous | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Lovastatin | Lovastatin | 29 | suppressed |
| Valproic Acid | Valproic Acid | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Nystop | Nystatin | 28 | 16 |
| Prednisolone Acetate | Prednisolone Acetate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 27 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Ixiaro | Japanese Encephalitis Vacc/Pf | 27 | 15 |
| Anastrozole | Anastrozole | 26 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 25 | suppressed |
| Acetazolamide | Acetazolamide | 24 | 18 |
| Digoxin | Digoxin | 24 | suppressed |
| Haloperidol | Haloperidol | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Levocarnitine | Levocarnitine | 24 | suppressed |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 23 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | 17 |
| Amoxicillin | Amoxicillin | 22 | 18 |
| Ceftriaxone | Ceftriaxone Sodium | 22 | 12 |
| Ixchiq | Chikungunya Vaccine, Live/Pf | 22 | 22 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 14 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 20 | suppressed |
| Heplisav-B | Hepatitis B Vaccine/Cpg1018/Pf | 20 | 15 |
| Levemir | Insulin Detemir | 20 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 14 |
| Mupirocin | Mupirocin | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Austedo | Deutetrabenazine | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 11 |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 18 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Clozapine | Clozapine | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Dexamethasone | Dexamethasone | 15 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | 13 |
| Ozempic | Semaglutide | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Glucagon Emergency Kit | Glucagon | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | 11 |
| Austedo Xr | Deutetrabenazine | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Glimepiride | Glimepiride | 13 | suppressed |
| Insulin Aspart | Insulin Aspart | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Meropenem | Meropenem | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Vaqta | Hepatitis A Virus Vaccine/Pf | 13 | 12 |
| Bexsero | Meningococcal B Vaccine,4-Comp | 12 | 11 |
| Dextrose In Water | Dextrose 5 % In Water | 12 | suppressed |
| Drospirenone-Ethinyl Estradiol | Ethinyl Estradiol/Drospirenone | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Menveo A-C-Y-W-135-Dip | Mening Vac A,c,y,w-135 Dip/Pf | 12 | 11 |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Pancreaze | Lipase/Protease/Amylase | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Travoprost | Travoprost | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,005.24 · 30 records | Teva Pharmaceuticals USA, Inc. | AIRSUPRA, AUSTEDO XR, CAPLYTA, CRYSVITA, Cologuard Collection Kit, DAYBUE, ELIQUIS, EPIDIOLEX, INGREZZA, MOUNJARO, NEFFY, NURTEC ODT, PAXLOVID, REBYOTA, REXULTI, The Cologuard Plus Collection Kit, VRAYLAR, Vivotif, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Austedo Xr play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error